Product
Unfractionated Heparin
Aliases
Unfractionated heparin
11 clinical trials
19 indications
Indication
COVID-19Indication
Venous ThromboembolismIndication
Arterial ThrombosisIndication
SepsisIndication
Radial Artery OcclusionIndication
Pregnancy RelatedIndication
Deep Vein Thrombosis (DVT)Indication
Coronary Artery DiseaseIndication
Ischaemic Heart DiseaseIndication
Anticoagulant-induced BleedingIndication
Coronary SyndromeIndication
ST Elevation Myocardial InfarctionIndication
Gram-Negative Bacterial InfectionsIndication
HeparinIndication
Critical IllnessIndication
Anticoagulant therapyIndication
Pediatric Acute Lymphoblastic LeukemiaIndication
Blood thinnersClinical trial
A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 PatientsStatus: Completed, Estimated PCD: 2022-03-10
Clinical trial
INHALEd Nebulised Unfractionated HEParin for the Treatment of Hospitalised Patients With COVID-19 (INHALE-HEP) AustraliaStatus: Withdrawn, Estimated PCD: 2023-12-01
Clinical trial
Use of Nafamostat Mesilate for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation After Cardiac Surgery: Efficacy and SafetyStatus: Not yet recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Comparative Study of Safety and Efficacy of Nafamostat Mesylate and Unfractionated Heparin in Renal Replacement Therapy for Sepsis Associated Acute Kidney Injury: A Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2027-04-01
Clinical trial
Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial.Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Randomized Control Trial of Unfractionated Heparin Thromboprophylaxis Dosing for Antepartum HospitalizationsStatus: Completed, Estimated PCD: 2022-03-31
Clinical trial
Low Dose Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection：a Pilot StudyStatus: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
Optimal Target of Activated Clotting Time During Percutaneous Coronary Intervention and Outcomes: The Randomized OPTIMAL-ACT TrialStatus: Completed, Estimated PCD: 2021-10-25
Clinical trial
Randomized Comparison of Anticoagulation After Primary Percutaneous Coronary Intervention Using Enoxaparin, ACT Guided Unfractionated Heparin or Bivalirudin Prolongation vs. no Anticoagulation To Improve Clinical OutcomeStatus: Completed, Estimated PCD: 2022-11-23
Clinical trial
Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation: a Randomized, Single-blind, Multicenter Exploratory, Heparin-controlled TrialStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane OxygenationStatus: Completed, Estimated PCD: 2021-10-08